Stock Events

Stock Events

Amarin 

$11.48
117
-$0.05-0.43%Tuesday 20:00
-$0.03-0.26%Tuesday 20:12After hours

Statistics

Day High
11.54
Day Low
11.49
52W High
20.9
52W Low
11.25
Volume
801
Avg. Volume
-
Mkt Cap
242.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Oct 29Expected
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
-0.61
-0.34
-0.08
0.19
Expected EPS
-0.03
Actual EPS
0.19

Financials

-18.16%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
213.65MRevenue
-38.8MNet Income

Analyst Ratings

$13.00Average Price Target
The highest estimate is ⁦13.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
0%
Sell
100%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMRN. It's not an investment recommendation.
Apple
22
AAPL
Tesla
22
TSLA
Microsoft
19
MSFT
Amazon
16
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca competes with Amarin in the cardiovascular drug market, particularly with drugs aimed at reducing triglyceride levels and improving heart health.
AMGEN
AMGN
Mkt Cap217.9B
Amgen offers a range of cardiovascular treatments that directly compete with Amarin's Vascepa, especially in the high triglyceride management space.
GSK
GSK
Mkt Cap94.23B
GlaxoSmithKline competes in the cardiovascular and metabolic disease areas, offering alternative treatments that could be used instead of Amarin's products.
Merck
MRK
Mkt Cap356.01B
Merck & Co. has a portfolio of cardiovascular drugs that can be seen as alternatives to Amarin's offerings, particularly in the lipid management space.
Pfizer
PFE
Mkt Cap158.45B
Pfizer has a broad range of cardiovascular drugs that compete with Amarin, including treatments for conditions that Vascepa is prescribed for.
Novartis
NVS
Mkt Cap268B
Novartis competes with Amarin in the heart health market, with drugs that offer similar benefits to Vascepa in reducing cardiovascular risk.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie, through its broad portfolio in the pharmaceutical sector, competes in the cardiovascular space, offering treatments that could serve as alternatives to Amarin's products.
Sanofi
SNY
Mkt Cap95.65B
Sanofi has a presence in the cardiovascular disease treatment market, competing with Amarin with its range of heart health medications.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals, in partnership with Sanofi, develops drugs that compete in the same therapeutic areas as Amarin, including cardiovascular health.

About

Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
Show More
CEO
Aaron D. Berg
Employees
80
Country
United Kingdom
ISIN
US0231114044
WKN
000A41557

Listings

F
DE
EH3.F
STU
DE
EH3.STU
MU
DE
EH3A.MU
MU
DE
EH3.MU

0 Comments

Share your thoughts

FAQs

What is Amarin stock price today?▼
The current price of AMRN is $11.48 USD — it has decreased by -0.43% in the past 24 hours. Watch Amarin stock price performance more closely on the chart.
What is Amarin stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Amarin stocks are traded under the ticker AMRN.
Is Amarin stock price growing?▼
AMRN stock has fallen by -1.12% compared to the previous week, the month change is a -14.84% fall, over the last year Amarin has showed a -42.43% decrease.
What is Amarin market cap?▼
Today Amarin has the market capitalization of 242.49M
What were Amarin earnings last quarter?▼
AMRN earnings for the last quarter are 0.19 USD per share, whereas the estimation was -0.03 USD resulting in a +733.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amarin revenue for the last year?▼
Amarin revenue for the last year amounts to 213.65M USD.
What is Amarin net income for the last year?▼
AMRN net income for the last year is -38.8M USD.
How many employees does Amarin have?▼
As of October 21, 2026, the company has 80 employees.
In which sector is Amarin located?▼
Amarin operates in the Health & Wellness sector.
When did Amarin complete a stock split?▼
The last stock split for Amarin was on April 11, 2025 with a ratio of 1:20.
Where is Amarin headquartered?▼
Amarin is headquartered in DUBLIN 2, United Kingdom.